Previous tests and indicators have suggested tirzepatide, which gained approval for use on the NHS this summer and will be marketed in UK as Mounjaro, achieves a weight loss of 22.5 per cent over 72 weeks, compared to 16 per cent over 68 weeks for Wegovy/Ozempic
The characteristics of the selected studies are provided in Tables 2 and 3
If your BMI falls between 27 and 29.9, you may still qualify if you have at least one weight-related condition such as sleep apnea, joint problems, or elevated blood pressure
Semaglutide for weight loss has become increasingly popular due to its effectiveness in helping individuals achieve significant results
The medication facilitates reduced calorie intake by managing appetite, but the nutritional composition of your diet determines whether you maintain muscle mass, meet micronutrient requirements, and establish sustainable eating patterns
Semaglutide is a glucagon-like peptide 1 agonist (GLP-1 agonist)